Phase 2 PLEIADES Study

Phase 2 PLEIADES Study

Mount Sinai Health System

3 months
45 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Ajai Chari, MD of @MountSinaiNYC discusses the phase 2 PLEIADES study.

_________

About the PLEIADES Trial
The non-randomized, open-label, parallel assignment Phase 2 PLEIADES (MMY2040) study included 199 adults with either newly diagnosed or relapsed/refractory multiple myeloma. Patients with newly diagnosed multiple myeloma were treated with 1,800 mg of the SC formulation in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory disease were treated with 1,800 mg of the SC formulation plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D-Rd cohorts was overall response rate. The primary endpoint for the D-VRd cohort was very good partial response or better rate. An additional cohort of patients with relapsed and refractory multiple myeloma treated with daratumumab plus carfilzomib and dexamethasone was subsequently added to the study.

Read here: https://www.oncologytube.com/video/new-darzalex-daratumumab-data-from-griffin-study-show-high-response-rate-and-depth-of-response-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible

Up Next Autoplay
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
TOURMALINE-MM4 Study
TOURMALINE-MM4 Study
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
Phase 3 Trial of NINLARO (ixazomib) as First Line Maintenance Therapy
Phase 3 Trial of NINLARO (ixazomib) as First Line Maintenance Therapy
Category: Multiple Myeloma
1 Views
Cancer-News 1 day
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Category: Multiple Myeloma
31 Views
ash 1 month
GRIFFIN Study Update #ASH19 @LevineCancer
GRIFFIN Study Update #ASH19 @LevineCancer
Category: Multiple Myeloma
3 Views
ash 1 month
Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus
Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus
Category: Multiple Myeloma
16 Views
ash 1 month
ICARIA-MM: What's Next? #ASH19
ICARIA-MM: What's Next? #ASH19
Category: Multiple Myeloma
6 Views
ash 1 month